Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Next Previous
Trial Profile

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDC 1421 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors BioLite Inc

Most Recent Events

  • 14 Nov 2024 According to a ABVC Biopharma media release, the Company is preparing for an FDA End-of-Phase 2 meeting to finalize the Phase III protocol.
  • 09 Oct 2023 According to an ABVC Biopharma media release, company has plans to initiate an End of Phase II (EOP II) meeting with the FDA.
  • 28 Feb 2020 According to an American BriVision Corporation media release, A Phase II Part II study is expected to follow at the UCSF Medical Center, along with major medical centers in Taiwan, after and subject to successful completion of this Phase II Part I study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top